MX2017004037A - Derivados de acido boronico. - Google Patents

Derivados de acido boronico.

Info

Publication number
MX2017004037A
MX2017004037A MX2017004037A MX2017004037A MX2017004037A MX 2017004037 A MX2017004037 A MX 2017004037A MX 2017004037 A MX2017004037 A MX 2017004037A MX 2017004037 A MX2017004037 A MX 2017004037A MX 2017004037 A MX2017004037 A MX 2017004037A
Authority
MX
Mexico
Prior art keywords
acid derivatives
boronic acid
lmp7
inhibitors
employed
Prior art date
Application number
MX2017004037A
Other languages
English (en)
Inventor
Klein Markus
Schadt Oliver
Haselmayer Philipp
Busch Michael
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2017004037A publication Critical patent/MX2017004037A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se relaciona con compuestos de la fórmula (I) como inhibidores de LPM7 y pueden emplearse, inter alia, para el tratamiento de un trastorno autoimnune o malignidades hematológicas.
MX2017004037A 2014-10-01 2015-10-01 Derivados de acido boronico. MX2017004037A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14003390 2014-10-01
PCT/EP2015/001930 WO2016050355A1 (en) 2014-10-01 2015-10-01 Boronic acid derivatives

Publications (1)

Publication Number Publication Date
MX2017004037A true MX2017004037A (es) 2017-07-04

Family

ID=51690787

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004037A MX2017004037A (es) 2014-10-01 2015-10-01 Derivados de acido boronico.

Country Status (14)

Country Link
US (1) US10640520B2 (es)
EP (1) EP3201205B1 (es)
JP (1) JP6835710B2 (es)
KR (1) KR20170066506A (es)
CN (1) CN107108660B (es)
AU (1) AU2015327411B2 (es)
BR (1) BR112017006368A2 (es)
CA (1) CA2963186A1 (es)
ES (1) ES2811273T3 (es)
IL (1) IL251300A0 (es)
MX (1) MX2017004037A (es)
RU (1) RU2017115193A (es)
SG (1) SG11201702625PA (es)
WO (1) WO2016050355A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX370336B (es) 2014-10-01 2019-12-10 Merck Patent Gmbh Derivados de acido boronico.
CA2963198A1 (en) 2014-10-01 2016-04-07 Merck Patent Gmbh Boronic acid derivatives
SG11201702628XA (en) 2014-10-01 2017-04-27 Merck Patent Gmbh Boronic acid derivatives
CN111601597B (zh) * 2017-08-23 2023-10-13 科智生命科学公司 自身免疫性病症的治疗中的免疫蛋白酶体抑制剂和免疫抑制剂
CN111183142B (zh) * 2017-08-24 2023-06-16 默克专利股份公司 硼酸衍生物
DK3826723T3 (da) 2018-07-26 2024-01-15 Merck Patent Gmbh Boronsyrederivater
TWI827694B (zh) * 2018-10-04 2024-01-01 美商凱薩爾生活科學公司 免疫蛋白酶體抑制劑調配物
CN113135944A (zh) * 2020-01-19 2021-07-20 首药控股(北京)有限公司 硼酸衍生物
CN113135943A (zh) * 2020-01-19 2021-07-20 首药控股(北京)有限公司 硼酸衍生物
CN114075227B (zh) * 2020-08-19 2023-07-04 北京嵩润医药科技有限责任公司 吡唑硼酸类化合物、包含其的药物组合物及它们的用途
IL310390A (en) 2021-07-29 2024-03-01 Merck Patent Gmbh Crystalline forms of [(R1)-2-benzofuran-3-yl)-1-{[(R4, R2, S1)-7-oxabicyclo[2.2.1]heptan-2-yl]formamido}ethyl]boronic acid, Their adducts and their use
WO2023232830A1 (en) 2022-06-02 2023-12-07 Merck Patent Gmbh Boronic acid adducts

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5563127A (en) * 1993-03-24 1996-10-08 The Dupont Merck Pharmaceutical Company Boronic acid and ester inhibitors of thrombin
IL111175A0 (en) * 1993-10-07 1994-12-29 Du Pont Merck Pharma Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them
US6060462A (en) * 1993-10-20 2000-05-09 Dupont Pharmaceuticals Company Electrophilic peptide analogs as inhibitors of trypsin-like enzymes
FR2758329B1 (fr) * 1997-01-16 1999-02-12 Synthelabo Derives d'imidazole-4-butane boronique, leur preparation et leur utilisation en therapeutique
US20100286092A1 (en) * 2007-11-13 2010-11-11 Burns Christopher J Beta-lactamase inhibitors
US20100120715A1 (en) * 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
AR075090A1 (es) * 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
MX352652B (es) * 2011-12-22 2017-12-04 Ares Trading Sa Inhibidores de inmunoproteasoma selectivos de derivados del acido alfa-amino boronico.
WO2014151958A1 (en) * 2013-03-14 2014-09-25 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
MX370336B (es) 2014-10-01 2019-12-10 Merck Patent Gmbh Derivados de acido boronico.
CA2963198A1 (en) 2014-10-01 2016-04-07 Merck Patent Gmbh Boronic acid derivatives
SG11201702628XA (en) 2014-10-01 2017-04-27 Merck Patent Gmbh Boronic acid derivatives

Also Published As

Publication number Publication date
AU2015327411B2 (en) 2020-01-02
JP6835710B2 (ja) 2021-02-24
US20180179231A1 (en) 2018-06-28
JP2018502049A (ja) 2018-01-25
RU2017115193A (ru) 2018-11-06
IL251300A0 (en) 2017-05-29
EP3201205A1 (en) 2017-08-09
RU2017115193A3 (es) 2019-02-08
BR112017006368A2 (pt) 2017-12-19
CN107108660A (zh) 2017-08-29
US10640520B2 (en) 2020-05-05
SG11201702625PA (en) 2017-04-27
ES2811273T3 (es) 2021-03-11
AU2015327411A1 (en) 2017-05-18
CA2963186A1 (en) 2016-04-07
CN107108660B (zh) 2020-09-15
WO2016050355A1 (en) 2016-04-07
KR20170066506A (ko) 2017-06-14
EP3201205B1 (en) 2020-05-13

Similar Documents

Publication Publication Date Title
PH12017500293A1 (en) Boronic acid derivatives
MX2017004043A (es) Derivados de acido boronico.
MX2017004037A (es) Derivados de acido boronico.
MX370336B (es) Derivados de acido boronico.
IL259787A (en) Mutant isocitrate dehydrogenase 1 (idh1) suppressor for the treatment of malignancies
PH12017500509A1 (en) Benzyl substituted indazoles as bub1 inhibitors
NZ724691A (en) Quinoline derivatives as smo inhibitors
MX2016012829A (es) Inhibidores de biaril cinasa.
TW201613886A (en) 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
IL261717A (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
PH12017500745A1 (en) Bromodomain inhibitors
NZ730603A (en) Mk2 inhibitors and uses thereof
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
AU2015299431B2 (en) Pyrrolidinone derivatives as metAP-2 inhibitors
PH12017501071A1 (en) Dihydropyrimidin-2-one compounds and medical use thereof
SG10201900564WA (en) Methods for treating cancer
MX366765B (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerósis múltiple.
MA39824A (fr) Composés azole amido-substitués
MX2016002924A (es) Inhibidores de cinasa a base de eter arilico.
MX2016009355A (es) Inhibidores de aril lactama cinasa.
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
EA201791099A1 (ru) Хинолин карбоксамиды для применения в лечении лейкоза
PH12016501182A1 (en) Novel compound for treatment of severe hypoglycemia
TN2016000180A1 (en) Novel compound for treatment of severe hypoglycemia.